For example, it was reported that fluvastatin could potentiate the anticancer activity of vorinostat in renal cancer cells by activating the mechanistic target of rapamycin (mTOR) inhibitor (AMP)-activated protein kinase adenosine monophosphate (AMPK) (41). Here, MTOR is linked to renal carcinoma.